Therefore, inhibition of WRN can enhance the cytotoxicity of PARP inhibitors (olaparib) in BRCA2-deficient ovarian cancer cells, suggesting that WRN may be used as an alternative or auxiliary target for PARP inhibitors [43]. This evidence concerns the gene BRCA2 and ovarian carcinoma.